Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results
Rhea-AI Summary
Belite Bio (NASDAQ: BLTE) will host a live webcast on March 2, 2026 at 4:30 p.m. ET to discuss preliminary, unaudited fourth quarter and full year 2025 financial results and provide a business update.
According to the company, the webcast link is available at the events page and a replay will be accessible for approximately 90 days after the event.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Biotech peers show mixed modest gains: names like TVTX and OCUL are up, and momentum scanner flags IBRX and TVTX moving higher, but there is insufficient data on BLTE’s own move to label this a sector-driven move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 10 | Q3 2025 earnings | Positive | +3.7% | Q3 2025 results, DRAGON completion, financings and strong cash position. |
| Aug 11 | Q2 2025 earnings | Positive | -0.5% | Q2 2025 results, Breakthrough Therapy status and PHOENIX enrollment progress. |
| May 13 | Q1 2025 earnings | Positive | +1.2% | Q1 2025 results, DRAGON DSMB support and PHOENIX enrollment update. |
| Mar 17 | FY 2024 earnings | Positive | +0.5% | FY 2024 results, cash/investments detail and Tinlarebant trial progress. |
| Nov 12 | Q3 2024 earnings | Positive | +3.2% | Q3 2024 results, DRAGON II dosing, PHOENIX enrollment and cash update. |
Past earnings/updates typically saw modest positive reactions around low-single-digit percentages, with only one mildly negative move.
Over the past year, Belite Bio’s earnings and corporate updates have paired financial reporting with steady clinical and regulatory progress. Events on Nov 10, 2025, Aug 11, 2025, and May 13, 2025 highlighted DRAGON and PHOENIX trial milestones, expanded cash balances, and additional financings. Price reactions around these earnings dates clustered near low-single-digit moves. Today’s planned webcast for preliminary Q4 and full-year 2025 results fits this pattern of using earnings dates as key clinical and funding update points.
Historical Comparison
Across the last five earnings-related releases, BLTE moved on average 1.61%. This webcast announcement fits the established pattern of earnings events tied to clinical and funding updates.
Earnings releases have traced Tinlarebant’s path from early DRAGON and PHOENIX enrollment through Phase 3 completion and growing cash resources via offerings and private placements.
Market Pulse Summary
This announcement schedules a webcast on March 2, 2026, to review preliminary, unaudited Q4 and full-year 2025 results and provide a business update. Historically, Belite Bio has used earnings events to pair financials with key Tinlarebant milestones and funding developments, with average moves near 1.61%. Investors may watch for updates on trial progress, cash runway, and any changes in development or commercialization plans discussed during the call and replay period.
AI-generated analysis. Not financial advice.
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, March 2, 2026, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the fourth quarter and full year ended December 31, 2025.
Webcast Information
Date: Monday, March 2, 2026
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link: https://events.q4inc.com/attendee/547616305
Webcast Link Instructions
You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects and is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent STGD1 subjects and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook,or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Sophie Hunt
belite@argotpartners.com
FAQ
When will Belite Bio (BLTE) present its Q4 and full year 2025 results?
How can investors join the Belite Bio (BLTE) March 2, 2026 webcast?
Will a replay of the Belite Bio (BLTE) March 2, 2026 webcast be available?
What topics will Belite Bio (BLTE) cover during the March 2, 2026 webcast?
What time is the Belite Bio (BLTE) webcast for West Coast investors on March 2, 2026?
